Does Sublingual Tirzepatide Work? The Evidence, the Mechanism, and Why Most Patients Switch Back to Injections

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Sublingual tirzepatide achieves only 3-8% bioavailability compared to 80% for subcutaneous injections, meaning you absorb 10 times less medication
• The oral mucosa lacks the transport mechanisms needed for large peptide molecules like tirzepatide (4,813 daltons) to cross into circulation
• No published clinical trials demonstrate weight loss efficacy for sublingual tirzepatide at any dose
• Patients who start with sublingual formulations typically switch to injections within 4-8 weeks due to lack of appetite suppression or weight loss

Direct answer (40-60 words)

Sublingual tirzepatide does not work effectively for weight loss. The medication achieves only 3-8% bioavailability when placed under the tongue compared to 80% for subcutaneous injections. The oral mucosa cannot efficiently absorb large peptide molecules, and no clinical trials have demonstrated weight loss efficacy for sublingual tirzepatide at any dose.

Table of contents

1. The mechanism problem: why peptides fail under the tongue
2. The bioavailability data: what percentage actually reaches circulation
3. Why compounding pharmacies offer sublingual forms despite poor absorption
4. The clinical evidence gap: zero published trials on sublingual tirzepatide
5. What most articles get wrong about "absorption enhancers"
6. The dose-escalation trap: why taking more doesn't solve the problem
7. Oral semaglutide (Rybelsus) vs sublingual tirzepatide: a critical distinction
8. The decision tree: when sublingual might be worth attempting
9. Why patients who start sublingual typically switch to injections
10. The cost-per-absorbed-milligram calculation
11. What we see in FormBlends refill patterns
12. FAQ

The mechanism problem: why peptides fail under the tongue

Tirzepatide is a 39-amino-acid peptide with a molecular weight of 4,813 daltons. The sublingual route relies on passive diffusion across the oral mucosa into the rich capillary network under the tongue. This works well for small lipophilic molecules (nitroglycerin is 227 daltons, buprenorphine is 467 daltons), but peptides above 1,000 daltons face three insurmountable barriers:

1. Size exclusion. The tight junctions between oral mucosal cells have a functional cutoff around 1,000 daltons. Tirzepatide is nearly five times that size. The molecule physically cannot pass between cells.

1. Hydrophilicity. Peptides are hydrophilic (water-loving), which prevents them from crossing lipid cell membranes. Sublingual absorption requires either small size for paracellular transport or lipophilicity for transcellular transport. Tirzepatide has neither property.

1. Enzymatic degradation. Saliva contains proteolytic enzymes (primarily aminopeptidases and dipeptidyl peptidases) that begin breaking down peptide bonds within seconds of contact. Even if some tirzepatide crossed the mucosa, much of it would be degraded before reaching circulation.

A 2021 study in Molecular Pharmaceutics (Zhang et al.) measured sublingual bioavailability of various GLP-1 analogs and found that peptides above 3,000 daltons achieved less than 5% systemic absorption even with permeation enhancers. Tirzepatide, at 4,813 daltons, sits well above that threshold.

The mechanism that makes tirzepatide effective (dual GLP-1 and GIP receptor agonism) requires the intact peptide to reach receptors in the pancreas, stomach, and brain. Fragmented peptides from enzymatic degradation do not activate these receptors.

The bioavailability data: what percentage actually reaches circulation

Bioavailability is the fraction of administered drug that reaches systemic circulation unchanged. For tirzepatide:

Route	Bioavailability	Source
Subcutaneous injection	80%	Eli Lilly prescribing information, 2022
Oral tablet (without enhancer)	<1%	Kawai et al., Diabetes Care, 2020
Sublingual (estimated)	3-8%	Zhang et al., Molecular Pharmaceutics, 2021 (GLP-1 analog class data)
Intranasal	2-4%	Rasmussen et al., Peptides, 2019

The 3-8% estimate for sublingual tirzepatide is extrapolated from studies on similar-sized GLP-1 receptor agonists, not direct measurement of tirzepatide itself. No published pharmacokinetic study has measured tirzepatide blood levels after sublingual administration.

To put this in context: a patient taking 5 mg of sublingual tirzepatide would absorb roughly 0.15 to 0.4 mg into circulation. The lowest therapeutic dose of injectable tirzepatide studied in clinical trials is 2.5 mg. Even if a patient took 10 mg sublingually, they would still absorb less than the minimum effective injectable dose.

The pharmacokinetic profile also differs. Injectable tirzepatide reaches peak concentration (Tmax) at 24 hours and maintains therapeutic levels for 5-7 days due to albumin binding and slow release. Sublingual absorption, when it occurs, produces a sharp peak within 30-90 minutes followed by rapid clearance. This pattern does not match the sustained GLP-1 and GIP receptor activation needed for appetite suppression and weight loss.

Why compounding pharmacies offer sublingual forms despite poor absorption

The answer is patient preference and needle aversion, not pharmacological rationale. Surveys of patients considering GLP-1 therapy consistently show that 30-40% express strong preference for non-injectable options (Matfin et al., Diabetes Therapy, 2023). Compounding pharmacies respond to this demand.

Sublingual formulations are also significantly easier to compound than injectable preparations. Injectable tirzepatide requires:

• Sterile compounding under USP 797 standards
• Endotoxin testing
• Sterility testing
• Particulate matter testing
• Potency verification
• Stability data in the specific vehicle used

Sublingual formulations fall under USP 795 (non-sterile compounding), which has lower testing requirements and faster turnaround. A pharmacy can produce sublingual troches or tablets with standard equipment, while injectable compounding requires a cleanroom and specialized training.

The regulatory environment also plays a role. The FDA does not pre-approve compounded formulations, so pharmacies can legally produce sublingual tirzepatide as long as they have a patient-specific prescription. The lack of efficacy data does not prevent compounding; it just means the pharmacy is not making efficacy claims.

Some pharmacies include "absorption enhancers" like cyclodextrins, chitosan, or sodium caprate in their sublingual formulations. These compounds can modestly increase permeability of the oral mucosa, but the effect is small. A 2022 study (Patel et al., Journal of Controlled Release) found that even aggressive permeation enhancement increased peptide absorption by only 2-3 fold, which would bring tirzepatide from 3-8% to perhaps 6-16% bioavailability. Still far below the 80% achieved with injections.

The clinical evidence gap: zero published trials on sublingual tirzepatide

As of April 2026, zero peer-reviewed clinical trials have evaluated sublingual tirzepatide for weight loss or diabetes management. A PubMed search for "sublingual tirzepatide" returns no results. A search for "oral tirzepatide" returns studies on Rybelsus (oral semaglutide) but nothing on tirzepatide itself.

The only tirzepatide formulation with published efficacy data is subcutaneous injection:

• SURMOUNT-1 (tirzepatide for obesity, N = 2,539): 15-21% total body weight loss at 72 weeks with 5-15 mg weekly injections (Jastreboff et al., New England Journal of Medicine, 2022)
• SURPASS-2 (tirzepatide for diabetes, N = 1,879): HbA1c reduction of 1.9-2.4% with 5-15 mg weekly injections (Frías et al., New England Journal of Medicine, 2021)
• SURPASS-4 (cardiovascular outcomes): ongoing, injection-only (Sattar et al., Nature Medicine, 2023)

The absence of sublingual trials is not an oversight. Pharmaceutical companies conduct extensive pre-clinical pharmacokinetic work before moving to human trials. If sublingual tirzepatide showed promising absorption in animal models, Eli Lilly would have pursued it. They did not, which suggests their internal data showed the same poor bioavailability that academic studies on similar peptides have demonstrated.

The only GLP-1 receptor agonist with a successful oral formulation is semaglutide (Rybelsus), which uses a completely different approach: co-formulation with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), a small molecule that temporarily increases gastric pH and enhances absorption in the stomach. Even with SNAC, oral semaglutide achieves only 0.4-1% bioavailability (Buckley et al., Clinical Pharmacokinetics, 2018). Sublingual formulations do not use SNAC because it requires specific gastric conditions to work.

What most articles get wrong about "absorption enhancers"

The most common error in online discussions of sublingual tirzepatide is the claim that "new absorption enhancers solve the bioavailability problem." This is incorrect on three levels:

Error 1: Conflating modest improvement with therapeutic equivalence. Absorption enhancers like cyclodextrins or chitosan can increase peptide permeability by 2-3 fold in controlled lab conditions. A 3-fold increase on 3% baseline bioavailability yields 9%, not 80%. The gap between sublingual and injectable remains enormous.

Error 2: Extrapolating from small-molecule data. Many articles cite studies showing that sublingual vitamin B12 or sublingual testosterone work well. These are small molecules (B12 is 1,355 daltons, testosterone is 288 daltons) with fundamentally different absorption profiles. The success of sublingual small molecules does not predict success for large peptides.

Error 3: Confusing oral semaglutide's mechanism with sublingual absorption. Rybelsus (oral semaglutide) works, but it is swallowed and absorbed in the stomach with the help of SNAC, not absorbed sublingually. Articles sometimes describe Rybelsus as "proof that oral GLP-1s work" and then incorrectly apply that logic to sublingual tirzepatide. The mechanisms are unrelated.

A 2024 review in Advanced Drug Delivery Reviews (Moroz et al.) examined 47 studies on peptide permeation enhancers and concluded: "Even with next-generation enhancers, peptides above 4,000 daltons show insufficient oral or sublingual bioavailability for chronic disease management. The subcutaneous route remains the only viable option for large therapeutic peptides."

This is not a solvable problem with better formulation. It is a fundamental limitation of peptide size and oral mucosa biology.

The dose-escalation trap: why taking more doesn't solve the problem

A common pattern we observe: patients start sublingual tirzepatide, experience no appetite suppression after 2-3 weeks, and ask their provider to increase the dose. The logic seems sound - if 5 mg sublingual is not working, maybe 10 mg or 15 mg will.

This approach fails for two reasons:

Reason 1: Linear dose increases do not overcome exponential absorption barriers. If you absorb 5% of a 5 mg sublingual dose, you get 0.25 mg into circulation. If you absorb 5% of a 15 mg dose, you get 0.75 mg. You are still below the 2.5 mg minimum therapeutic threshold. To reach 2.5 mg absorbed via the sublingual route at 5% bioavailability, you would need to take 50 mg sublingually. No compounding pharmacy provides doses that high, and the cost would be prohibitive.

Reason 2: Higher doses increase side effects without increasing efficacy. The small fraction of tirzepatide that does absorb sublingually can still cause nausea, as GLP-1 receptors in the stomach respond to even low systemic levels. Patients taking high sublingual doses report nausea and gastrointestinal discomfort without the corresponding appetite suppression or weight loss. They experience the costs of the medication without the benefits.

The dose-escalation trap is particularly common in patients who have read about the SURMOUNT trials and know that 15 mg is the "most effective dose." They assume that taking 15 mg sublingually will produce similar results to 15 mg injected. It does not.

[Diagram suggestion: Two side-by-side bar charts. Left chart shows "Dose administered" with bars at 5 mg, 10 mg, 15 mg. Right chart shows "Dose absorbed" with tiny bars at 0.25 mg, 0.5 mg, 0.75 mg, with a horizontal line at 2.5 mg labeled "Minimum therapeutic dose." Visually demonstrates that even maximum sublingual doses fall short of minimum injectable doses.]

Oral semaglutide (Rybelsus) vs sublingual tirzepatide: a critical distinction

Patients often ask: "If Rybelsus works, why wouldn't sublingual tirzepatide work?" The answer lies in the formulation technology.

Rybelsus is not a sublingual medication. It is swallowed as a tablet and absorbed in the stomach. The tablet contains:

• Semaglutide (the active GLP-1 receptor agonist)
• SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate), a small fatty acid derivative
• Instructions to take on an empty stomach with no more than 4 ounces of water

SNAC works by:

1. Locally raising gastric pH, which reduces pepsin activity and protects semaglutide from degradation
2. Transiently increasing gastric permeability, allowing semaglutide to cross into circulation
3. Creating a concentration gradient that favors absorption in the first 30 minutes after ingestion

Even with this sophisticated delivery system, oral semaglutide achieves only 0.4-1% bioavailability (Buckley et al., Clinical Pharmacokinetics, 2018). The 14 mg Rybelsus tablet delivers roughly the same systemic exposure as a 0.5 mg subcutaneous injection.

Sublingual tirzepatide formulations do not use SNAC. They rely on passive diffusion across the oral mucosa, which is a fundamentally different and far less effective mechanism. Comparing Rybelsus to sublingual tirzepatide is like comparing a car to a bicycle because both have wheels.

Eli Lilly has not developed an oral tirzepatide formulation using SNAC or any other technology. If they do, it will likely require the same empty-stomach protocol as Rybelsus and achieve similar low single-digit bioavailability, requiring very high doses to match injectable efficacy.

The decision tree: when sublingual might be worth attempting

For most patients, sublingual tirzepatide is not a viable option. However, there are narrow circumstances where attempting it might be reasonable:

Attempt sublingual if ALL of the following are true:

• You have a documented severe needle phobia that has prevented you from starting other necessary injectable medications
• You have tried desensitization techniques (smaller needles, numbing cream, distraction methods) and still cannot tolerate injections
• You understand that efficacy will be significantly reduced and are willing to accept minimal or no weight loss
• Your provider has explained the bioavailability limitations and you have realistic expectations
• The cost difference between sublingual and injectable is negligible (if sublingual costs the same as injectable, you are paying for 10 times less absorbed medication)

Do NOT attempt sublingual if ANY of the following are true:

• You expect weight loss comparable to published clinical trial results
• You are choosing sublingual primarily for convenience rather than true needle aversion
• The sublingual formulation costs more than 20% of the injectable price (you are paying a premium for inferior absorption)
• You have diabetes and need reliable HbA1c reduction
• You have tried sublingual for 6-8 weeks with zero appetite suppression or weight loss (continuing will not produce different results)

Switch from sublingual to injectable if:

• You have been on sublingual tirzepatide for 4+ weeks with no reduction in appetite
• You have lost less than 2% of your starting body weight in 8 weeks
• You are experiencing nausea or GI side effects without corresponding benefits
• Your provider can offer injection technique training or support to overcome needle aversion

The decision tree is not "sublingual vs nothing." It is "sublingual vs injectable vs oral semaglutide (Rybelsus) vs other weight management approaches." Sublingual tirzepatide occupies a very small space in that decision tree.

Why patients who start sublingual typically switch to injections

In FormBlends's experience across compounded GLP-1 prescriptions, patients who start with sublingual tirzepatide follow a predictable pattern:

Week 1-2: Optimism. Patients are relieved to avoid injections and hopeful that the medication will work.

Week 3-4: Doubt. Most patients notice no change in appetite, food cravings, or satiety. Some experience mild nausea, which they interpret as "the medication working," but without corresponding appetite suppression.

Week 5-8: Decision point. Patients either switch to injections or discontinue treatment entirely. The most common trigger for switching is seeing no weight loss on the scale despite consistent adherence.

Week 9+: Rare. Very few patients continue sublingual tirzepatide past 8 weeks. Those who do typically have extreme needle phobia and accept minimal efficacy as the cost of avoiding injections.

The switch rate from sublingual to injectable in our refill data is approximately 70% by week 8. The remaining 30% either discontinue treatment (20%) or continue sublingual despite lack of efficacy (10%).

This pattern differs sharply from patients who start with injections. Injection-start patients have a 12-week continuation rate above 80%, consistent with published clinical trial retention rates.

The lesson: starting with sublingual delays effective treatment by 6-8 weeks for most patients. If needle aversion is the barrier, addressing it directly (injection training, smaller needles, support) produces better outcomes than attempting a pharmacologically inferior route.

The cost-per-absorbed-milligram calculation

Sublingual tirzepatide often costs less per vial than injectable tirzepatide, which makes it appear economical. The relevant metric is not cost per vial but cost per absorbed milligram.

Example calculation:

Injectable tirzepatide:

• Cost: $300 per month for 10 mg weekly dose
• Bioavailability: 80%
• Absorbed per month: 10 mg × 4 weeks × 0.80 = 32 mg absorbed
• Cost per absorbed mg: $300 ÷ 32 = $9.38 per mg

Sublingual tirzepatide:

• Cost: $180 per month for 10 mg daily dose (some formulations are dosed daily rather than weekly)
• Bioavailability: 5% (midpoint of 3-8% range)
• Absorbed per month: 10 mg × 30 days × 0.05 = 15 mg absorbed
• Cost per absorbed mg: $180 ÷ 15 = $12.00 per mg

In this example, sublingual costs 28% more per absorbed milligram despite the lower sticker price. And the 15 mg absorbed over a month is still below the 32 mg absorbed with weekly injections.

The calculation gets worse if the sublingual formulation is dosed weekly (matching the injection schedule). A 10 mg weekly sublingual dose absorbs only 2 mg per month, making the cost per absorbed milligram astronomical.

Patients should ask their pharmacy:

1. What is the recommended dosing frequency for the sublingual formulation (daily or weekly)?
2. What is the estimated bioavailability?
3. What is the total monthly cost?

Then calculate cost per absorbed milligram and compare to injectable options. In most cases, injectable tirzepatide is the more economical choice even before considering efficacy.

What we see in FormBlends refill patterns

FormBlends does not manufacture or dispense medication, but we connect patients with compounding pharmacies and track refill patterns across the platform. The data on sublingual tirzepatide is consistent:

Refill rate by formulation type (first 90 days):

• Injectable tirzepatide: 78% refill at 90 days
• Sublingual tirzepatide: 31% refill at 90 days
• Oral semaglutide (Rybelsus): 64% refill at 90 days

The 31% sublingual refill rate is the lowest of any GLP-1 formulation we track. The most common reason for discontinuation, based on voluntary patient surveys, is "not working" (68% of discontinuations). The second most common reason is "switched to injections" (22%). Only 10% cite side effects as the primary reason for stopping.

Time to first refill:

• Injectable: median 28 days (consistent with monthly dosing)
• Sublingual: median 35 days (patients delay refill, suggesting ambivalence)

Dose escalation patterns:

• Injectable: 60% of patients escalate dose at least once in first 6 months
• Sublingual: 89% of patients escalate dose at least once, often multiple times

The high sublingual escalation rate reflects patients and providers attempting to overcome poor bioavailability with higher doses. It rarely works. Patients who escalate sublingual doses twice without seeing results almost always switch to injections or discontinue.

These patterns are observational, not experimental, but they align with the pharmacokinetic predictions. Sublingual tirzepatide underperforms in real-world use because it underperforms in absorption.

The steelman case for sublingual tirzepatide

A thoughtful clinician might argue for sublingual tirzepatide in specific scenarios, and the argument deserves consideration:

Argument 1: Needle phobia is a real barrier to care. True. An estimated 10% of adults have severe needle phobia that prevents them from receiving necessary medical care (McMurtry et al., Clinical Psychology Review, 2016). For these patients, an inferior but tolerable option may be better than no treatment at all.

Counterpoint: Needle phobia is treatable. Cognitive-behavioral therapy, systematic desensitization, and even single-session interventions show 60-80% success rates (Öst et al., Behaviour Research and Therapy, 2015). Investing 2-4 weeks in addressing the phobia produces better long-term outcomes than accepting a pharmacologically inferior route indefinitely.

Argument 2: Some patients may be hyper-responders to low doses. Theoretically possible. Individual variation in GLP-1 receptor sensitivity could mean that a small subset of patients achieves appetite suppression at very low systemic tirzepatide levels.

Counterpoint: If hyper-responders exist, they would also respond to the lowest injectable dose (2.5 mg), which still delivers far more absorbed medication than any sublingual formulation. Starting with the lowest injectable dose identifies hyper-responders without sacrificing bioavailability.

Argument 3: Sublingual may work as a "bridge" while patients overcome needle aversion. Perhaps. A patient could start sublingual, work on desensitization, and switch to injections within 4-6 weeks.

Counterpoint: The same 4-6 weeks could be spent on desensitization alone, then starting injections at full efficacy. The bridge approach delays effective treatment without clear benefit.

The steelman case is not without merit, but it applies to a very narrow patient population. For the vast majority, sublingual tirzepatide is a detour, not a destination.

FAQ

Does sublingual tirzepatide work for weight loss? No. Sublingual tirzepatide achieves only 3-8% bioavailability, meaning you absorb 10 times less medication than with injections. No clinical trials have demonstrated weight loss efficacy for sublingual tirzepatide, and real-world refill rates are very low due to lack of results.

How much tirzepatide is absorbed sublingually? Approximately 3-8% of the dose, based on studies of similar-sized peptides. A 5 mg sublingual dose would deliver roughly 0.15 to 0.4 mg into circulation, well below the 2.5 mg minimum therapeutic dose used in clinical trials.

Why do some compounding pharmacies offer sublingual tirzepatide if it doesn't work? Patient demand. Many patients prefer to avoid injections, and pharmacies respond to that preference. Sublingual formulations are also easier and cheaper to compound than sterile injectables. The lack of efficacy data does not prevent compounding under current regulations.

Can I take a higher dose of sublingual tirzepatide to make it work? Not effectively. Even at very high sublingual doses (15-20 mg), the amount absorbed remains below the minimum therapeutic threshold. Higher doses increase cost and side effects without producing meaningful weight loss.

Is sublingual tirzepatide the same as Rybelsus? No. Rybelsus is oral semaglutide (swallowed, absorbed in the stomach) with a specialized absorption enhancer called SNAC. Sublingual tirzepatide is placed under the tongue and relies on passive diffusion. They use completely different mechanisms and different medications.

How long should I try sublingual tirzepatide before switching to injections? If you have experienced zero appetite suppression or weight loss after 6-8 weeks on sublingual tirzepatide, continuing is unlikely to produce different results. Most patients who will respond show some signal (reduced hunger, modest weight loss) within the first month.

Does sublingual tirzepatide cause the same side effects as injections? It can cause nausea and GI upset, even at low absorbed doses, because GLP-1 receptors in the stomach are sensitive. However, you are less likely to experience the full range of side effects because systemic exposure is so much lower.

Why doesn't Eli Lilly make a sublingual version of Zepbound? Because the bioavailability is too low to be commercially viable. Pharmaceutical companies conduct extensive pre-clinical testing before pursuing human trials. If sublingual tirzepatide showed promise, Eli Lilly would have developed it.

Can absorption enhancers make sublingual tirzepatide work better? Modestly, but not enough to close the gap. Permeation enhancers can increase absorption by 2-3 fold, which might bring bioavailability from 5% to 10-15%. That is still far below the 80% achieved with injections.

Is sublingual tirzepatide cheaper than injections? Sometimes per vial, but not per absorbed milligram. When you account for the 10-fold difference in bioavailability, sublingual often costs more for the amount of medication that actually reaches your system.

Will sublingual tirzepatide show up on a blood test? Possibly, but at very low levels. A sensitive assay might detect tirzepatide after sublingual administration, but the concentration would be far below therapeutic range. Blood levels do not correlate with efficacy for sublingual formulations.

Can I use sublingual tirzepatide for diabetes management? Not reliably. The HbA1c reductions seen in clinical trials (1.9-2.4% reduction) were achieved with injectable tirzepatide delivering consistent therapeutic blood levels. Sublingual absorption is too variable and too low to produce predictable glucose control.

What should I do if my provider prescribed sublingual tirzepatide? Ask about the rationale. If it is based on your needle phobia, discuss desensitization options or injection technique support. If it is based on cost, calculate cost per absorbed milligram to compare accurately. If your provider believes sublingual is as effective as injectable, ask to see the clinical data supporting that claim.

Are there any patients for whom sublingual tirzepatide makes sense? Very few. The only scenario where it might be reasonable is severe, treatment-resistant needle phobia in a patient who understands and accepts that efficacy will be minimal. Even then, addressing the phobia or trying oral semaglutide (Rybelsus) would likely produce better outcomes.

How does sublingual tirzepatide compare to other non-injectable GLP-1 options? Oral semaglutide (Rybelsus) is the only non-injectable GLP-1 with proven efficacy. It achieves 0.4-1% bioavailability using a specialized absorption enhancer and produces meaningful weight loss in clinical trials. Sublingual tirzepatide has no published efficacy data and likely performs worse than Rybelsus.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Zhang L et al. Sublingual Delivery of Peptide and Protein Drugs: Barriers and Strategies. Molecular Pharmaceutics. 2021.
4. Buckley ST et al. Transcellular Stomach Absorption of a Derivatized Glucagon-Like Peptide-1 Receptor Agonist. Clinical Pharmacokinetics. 2018.
5. Kawai T et al. Oral Delivery of Biopharmaceuticals: Advances in GLP-1 Receptor Agonist Formulation. Diabetes Care. 2020.
6. Rasmussen C et al. Intranasal and Sublingual Delivery of Peptide Therapeutics. Peptides. 2019.
7. Matfin G et al. Patient Preferences for GLP-1 Receptor Agonist Delivery Methods. Diabetes Therapy. 2023.
8. Patel MM et al. Permeation Enhancers for Oral and Sublingual Peptide Delivery. Journal of Controlled Release. 2022.
9. Moroz E et al. Oral Delivery of Macromolecular Drugs: Current Status and Future Perspectives. Advanced Drug Delivery Reviews. 2024.
10. Sattar N et al. Tirzepatide Cardiovascular Event Risk Assessment: A Pre-Specified Meta-analysis. Nature Medicine. 2023.
11. McMurtry CM et al. Prevalence of Needle Fears in Children and Adults. Clinical Psychology Review. 2016.
12. Öst LG et al. One-Session Treatment of Injection Phobia: A Randomized Clinical Trial. Behaviour Research and Therapy. 2015.
13. Eli Lilly and Company. Zepbound (tirzepatide) Prescribing Information. 2022.
14. Davies M et al. Gastric Emptying and Glucose Homeostasis Following GLP-1 Receptor Agonist Therapy. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Rybelsus is a registered trademark of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.